{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:30:56Z","timestamp":1778599856656,"version":"3.51.4"},"reference-count":27,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T00:00:00Z","timestamp":1441238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"LEO Pharma BV"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Topical therapies are the mainstay of treatment for psoriasis vulgaris. The fixed combination of calcipotriol (Cal) 50\u00a0<jats:italic>\u03bc<\/jats:italic>g\/g plus betamethasone 0.5\u00a0mg\/g (as dipropionate; <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>) is a first\u2010line topical treatment and available as a gel or ointment. The use of these fixed combination products was compared in <jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\u2010long, a long\u2010term noninterventional study, for which interim results (4 and 12\u00a0weeks) have previously been reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To describe and compare patients\u2019 perspectives on the fixed combination gel and ointment formulations; to include efficacy, adherence behaviour, treatment satisfaction and health\u2010related quality of life (<jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL) aspects during long\u2010term real\u2010life psoriasis management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">PRO<\/jats:styled-content>\u2010long was a multicentre, prospective, observational, 52\u2010week study of patients prescribed fixed combination Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> gel or ointment in clinical practice. For final analysis the following were assessed at weeks 24, 36 and 52: differences in the proportion of patients with \u2018mild\u2019\/\u2018very mild\u2019 disease according to patient's global assessment of disease severity, adherence behaviour, treatment satisfaction (nine\u2010item treatment satisfaction questionnaire for medication) and <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL (Skindex\u201029).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients (<jats:italic>n\u00a0<\/jats:italic>=\u00a0328) were prescribed once\u2010daily Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> gel (<jats:italic>n<\/jats:italic>\u00a0=\u00a0152) or ointment (<jats:italic>n<\/jats:italic>\u00a0=\u00a0176). At week 52, a higher proportion of patients reported that the severity of their psoriasis was \u2018mild\u2019\/\u2018very mild\u2019 vs. baseline (gel: 60.2 vs. 47.1%; ointment: 58.8 vs. 42.4%), with greater treatment satisfaction reported in patients using gel vs. those using ointment. A higher proportion of patients found the gel \u2018easy\u2019 to use compared with the ointment (66.7 vs. 45.2%). Daily application of treatment took \u22645\u00a0min for 86.1% of patients using gel and 71.0% of patients using ointment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This real\u2010life study has demonstrated similar effectiveness between the Cal\/<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> formulations. However, over a 52\u2010week treatment period, patients reported greater treatment satisfaction with the gel, which was considered easier to use, faster to apply and overall a more convenient product.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13230","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T03:39:37Z","timestamp":1441337977000},"page":"2349-2355","source":"Crossref","is-referenced-by-count":36,"title":["Real\u2010life effectiveness of once\u2010daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52\u2010week <scp>PRO<\/scp>\u2010long study"],"prefix":"10.1111","volume":"29","author":[{"given":"J.","family":"Lambert","sequence":"first","affiliation":[{"name":"Department of Dermatology Ghent University Hospital Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.W.","family":"Hol","sequence":"additional","affiliation":[{"name":"LEO Pharma BV Amsterdam Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Vink","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Centrum Haaglanden Westeinde Hospital The Hague Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000092283"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.319"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506060-00005"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.12.032"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12174"},{"key":"e_1_2_6_12_1","unstructured":"HolK.Patient preference for topical psoriasis formulations. Poster presented at theEADV Congress Gothenburg Sweden 6\u201310October 2010; abst: P572."},{"key":"e_1_2_6_13_1","first-page":"327","article-title":"Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference","volume":"70","author":"Housman TS","year":"2002","journal-title":"Cutis"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04060.x"},{"key":"e_1_2_6_15_1","first-page":"304","article-title":"Calcipotriene 0.005%\u2010betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference","volume":"94","author":"Sandoval LF","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_6_16_1","first-page":"32","article-title":"The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis","volume":"79","author":"Stein Gold L","year":"2007","journal-title":"Cutis"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04525.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04059.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04518.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12387"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890470111018"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06174.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.052"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.005"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000155642"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12443"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13230","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:03:28Z","timestamp":1695542608000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,3]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/jdv.13230"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13230","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,3]]}}}